zurück

Risankizumab (new indication: psoriatic arthritis, monotherapy or in combination with methotrexate)

Subject:

Time table:

Final decision:

Patients who have had an inadequate response to or have been intolerant of prior disease-modifying antirheumatic (DMARD) therapy: No additional benefit proved
Patients who have had an inadequate response to or have not tolerated, prior therapy with disease-modifying biologic antirheumatic drugs (bDMARDs): No additional benefit proved